

Draft Provisional SIM Quality Council Measure Set 6-14-15

DRAFT

Consumer Experience Measure	NQF	ACO
PCMH – CAHPS	0005	
Prevention Measure	NQF	ACO
Breast cancer screening	2372	20
Cervical cancer screening	0032	
Chlamydia screening in women	0033	
Colorectal cancer screening	0034	19
Preventive care and screening: influenza immunization	0041	14
Adolescent female immunizations HPV	1959	
<i>Weight assessment and counseling for nutrition and physical activity for children/adolescents</i>		
Preventative care and screening: BMI screening and follow up	0421	16
Developmental screening in the first three years of life	1448	
Well-child visits in the first 15 months of life	1392	
Well-child visits in the third, fourth, fifth and sixth years of life	1516	
Adolescent well-care visits		
Tobacco use screening and cessation intervention	0028	17
Preventive care and screening: screening for high blood pressure and follow-up documented		21
Prenatal Care & Postpartum care	1517	
Frequency of Ongoing Prenatal Care (FPC)	1391	
Oral health: Primary Caries Prevention	1419	
Behavioral Health Measure	NQF	ACO
Follow-up care for children prescribed ADHD medication	0108	
Depression Remission at 12 Twelve Months	0710	
Child and Adolescent Major Depressive Disorder (MDD): Suicide Risk Assessment	1365	
Unhealthy Alcohol Use – Screening	PQRS 173	
Screening for clinical depression and follow-up plan	0418	18
Maternal depression screening	1516	
Pediatric behavioral health screening	0722	
Obstetrics Measure	NQF	ACO
Elective Delivery	0469	
Care coordination/patient safety	NQF	ACO
Documentation of current medications in the medical record	0419	39
Annual monitoring for persistent medications (roll-up)	2371	

Acute & Chronic Care Measure	NQF	ACO
Medication management for people with asthma	1799	
Disease modifying anti-rheumatoid arthritis	0054	
DM: Hemoglobin A1c Poor Control (>9%)	0059	27
DM: Diabetes eye exam	0055	41
DM: Diabetes foot exam	0057	
DM: Diabetes: medical attention for nephropathy	0062	
HTN: Controlling high blood pressure	0018	28
CHF: beta-blocker therapy for left ventricular systolic dysfunction	0083	31
Use of spirometry testing in the assessment and diagnosis of COPD	0577	
CAD: Persistence of Beta blocker therapy after a heart attack	0071	
CAD: Medication adherence	0543	
Use of imaging studies for low back pain	0052	
Avoidance of antibiotic treatment in adults with acute bronchitis	0058	
Appr. treatment for children with upper respiratory infection	0069	
Ischemic vascular disease: use of aspirin or another antithrombotic	0068	30

Measures UNDER REVIEW	NQF	ACO
Risk standardized all condition readmission	1789	8
Plan all-cause readmission	1768	
Skilled Nursing Facility 30-day All-Cause Readmission Measure (SNFRM)		35
All-cause unplanned admissions for patients with DM		36
All-cause unplanned admissions for patients with heart failure		37
All-cause unplanned admission for multiple chronic conditions (MCC)		38
Ambulatory Sensitive conditions admissions: chronic obstructive pulmonary disease (COPD) or asthma in older adults	0275	9
Ambulatory sensitive conditions admissions: heart failure (HF)	0277	10
Ambulatory sensitive condition composite admissions		
Pediatric ambulatory care sensitive condition composite admissions		
Hospital admissions for asthma (adults)	0283	
Annual % asthma patients (2-20) with 1 or more asthma-related ED visits		
Potentially avoidable ER rate		
Hospital admissions for asthma (child)	0728	
% adults w/ inpatient “medicine” admissions with post-admission follow-up within 7 days		
Adult major depressive disorder (MDD): Coordination of care of patients with specific comorbid conditions		
Annual Dental Visit (ADV)	1388	
Oral Evaluation, Dental Services	2517	
Annual Dental Visit (Medicaid, Chip)		
Gap in HIV medical visits	2080	
HIV/AIDS: Screening for Chlamydia, Gonorrhea, and Syphilis	0409	
HIV viral load suppression	2082	

Italicized measures = proposed data source is the Electronic Health Record
 NQF #s with strike out are no longer NQF endorsed

Reporting Only Measures & Measures Not Currently Recommended for Payment

DRAFT

Recommended for Reporting	NQF	ACO
Anti-Depressant Medication Management	0105	
Initiation and Engagement of Alcohol and Other Drug Dependence Treatment	0004	
Follow up after hospitalization for mental illness, 7 & 30 days		
30 day readmission (MMDLN)		
% PCPs that meet Meaningful Use		11

Consumer Experience Measure	NQF	ACO
ACO – CAHPS		1-7

Preventative Health	NQF	ACO
Lead screening in children		
Glaucoma screening		
Childhood immunizations DTaP and IPV		
Childhood immunizations MMR	0038	
Childhood immunizations VZV	0038	
Childhood immunizations status combo 2,3,4	0038	
Adolescent immunizations TDaP/TD & meningococcal	0038	
Adult BMI assessment		
Pneumonia vaccination status, older adults**	0043	15
Osteoporosis management in women who had a fracture**	0053	
Medication Adherence, 81 years & older**		
Topical Fluoride for Children at Elevated Caries Risk, Dental Services	2528	

Acute Care	NQF	ACO
Appr. testing for children with pharyngitis	0002	
Episiotomy in vaginal deliveries	0470	
Use of appropriate medication for people with asthma	0036	

Behavioral Health Measure	NQF	ACO
Bipolar & Major Depression: Appraisal for Alcohol or Chemical Substance Use		
Depression Utilization of the PHQ-9 Tool	0712	
Adherence to Antipsychotic Medications for Individuals with Schizophrenia	1879	
Tobacco Use and Help with Quitting Among Adolescents		
% of adults given a new psychiatric diagnoses, and medication, by a PCP who received a F/U within 30 days (DSS custom)		

At-Risk Population	NQF	ACO
HTN: Serum creatinine testing	0605	
HTN: Diuretics Persistent use with lab monitoring		
HTN: Medication adherence		
Ischemic stroke: Warfarin: PT/INR monitoring	0612	
Ischemic vascular disease: complete lipid panel and LDL control	0073	29
Ischemic vascular disease: MI, CABG, PCI or IVD with complete lipid profile		
Ischemic vascular disease: LDL>=100 and treated with lipid lowering agent, or LDL<100	0075	
Ischemic vascular disease : LDL-C screening for patients with cardiovascular conditions		
Heart failure: beta-blocker therapy	0615	
Digoxin: Persistent use with lab monitoring	2371	
COPD: Pharmacotherapy management of COPD exacerbation	0549	
CAD: Coronary artery disease all-or-nothing composite: Lipid Control	0074	32
CAD: Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker (ACE-I/ARB) therapy—diabetes or left ventricular systolic dysfunction	0066	33
CAD: Antiplatelet therapy	2379	43
CAD: Symptom management – CAD pt seen within 12 months for angina symptoms		44
CAD: Beta blocker therapy prior MI or LVEF	0070	45
CAD: Lipid lowering drug for LDL>30		
CAD: Post-MI use of ACE-I/ARB w/ h/o, HTN, DM, or HF	0594	
CAD: Drug-eluting stent: antiplatelet therapy	2379	
Migraine: Frequent use of acute meds/ receiving prophylactic meds	0602	
Otitis Media with Effusion: Tympanostomy tube insertion: pediatric hearing test	0587	
Potentially harmful drug-disease interactions		

Care coordination/patient safety	NQF	ACO
Falls: screening for future fall risk**	0101	13
Use of high-risk medications in the elderly**	0022	
% of prescribers that use e-prescribing		
Adverse event rate – outpatient procedures		

**Under consideration for older adults
NQF #s that are crossed out are no longer NQF endorsed

At-Risk Population	NQF	ACO
DM: High blood pressure control	0061	
DM: Hemoglobin A1C control (<8%)	0575	
DM: Tobacco non-use		
DM: Low density lipoprotein (LDL-C) control	0064	
DM: Low density lipoprotein (LDL-C) screening	0063	
Diabetes treatment medication for HTN	0546	
Diabetes: A1C testing	0057	
Diabetes: A1C testing pediatric	0061	
Diabetes kidney disease monitoring/urine protein screening		
Comprehensive diabetes care		
Diabetes: annual lipid profile		
Diabetes: blood pressure management (<140/80)		
Diab: LDL=>100 & lipid lowering agent use		
% OF Metformin use for diabetic and pre-diabetic members (UCLA study)		
Diabetes: Medication adherence	2468	
Epilepsy: Anticonvulsants: Persistent use with lab monitoring		
Epilepsy: Carbamazepine: Persistent use with lab monitoring		
Epilepsy: Phenobarbital: Persistent use with lab monitoring		
Epilepsy: Phenytoin: Persistent use with lab monitoring		
Epilepsy: Valproic acid: Persistent use with lab monitoring		
Cesarean section rate in singleton low risk deliveries	0471	
Colorectal cancer: follow-up after treatment		
CAD: ACE-I/ARB: Persistent use with lab monitoring	2371	

Access and Availability of Care	NQF	ACO
Children and adolescents access to primary care practitioners	NQMC - 9059	
Adults access to preventive/ambulatory health services	NCMC – 9058	

Resource Efficiency	
Bed days/1000	ER repeat visit rate
Generic dispensing/substitution	% of members with 3 or more ER visits
ER: ambulatory visits/1k	EOC efficiency index
Non-emergent ER visits/1000	Amb Surgery Steerage
% of ER visits Non-emergent	Radiology Steerage